Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Ramez Eskander

    TitleAssistant Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentReproductive Medicine
    Address9500 Gilman Drive #0987
    CA La Jolla 92093
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Clair K, Wolford J, Veran-Taguibao S, Kim G, Eskander R. Primary low-grade endometrial stromal sarcoma of the omentum. Gynecol Oncol Rep. 2017 Aug; 21:119-121. PMID: 28831418.
        View in: PubMed
      2. Paraghamian SE, Longoria TC, Eskander R. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract. 2017; 4:3. PMID: 28174665.
        View in: PubMed
      3. Eskander R, Carpenter BA, Wu HG, Wolf JK. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients. Curr Med Res Opin. 2016 Jun; 32(6):1161-5. PMID: 27052730.
        View in: PubMed
      4. Longoria TC, Eskander R. Erratum to: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2016; 3:2. PMID: 27232495; PMCID: PMC4881200.
      5. Eskander R, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32. PMID: 26397159.
        View in: PubMed
      6. Longoria TC, Eskander R. Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015; 2:11. PMID: 27231571; PMCID: PMC4881063.
      7. Tewari KS, Java JJ, Eskander R, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016 Jan; 27(1):114-21. PMID: 26487588; PMCID: PMC4684156 [Available on 01/01/17].
      8. Tewari KS, Eskander R, Monk BJ. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3829-35. PMID: 26169965.
        View in: PubMed
      9. Grove N, Zheng M, Bristow RE, Eskander R. Extensive Tattoos Mimicking Lymphatic Metastasis on Positron Emission Tomography Scan in a Patient With Cervical Cancer. Obstet Gynecol. 2015 Jul; 126(1):182-5. PMID: 25923020.
        View in: PubMed
      10. Ji T, Guo Y, Kim K, McQueen P, Ghaffar S, Christ A, Lin C, Eskander R, Zi X, Hoang BH. Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma. Mol Cancer. 2015 Apr 17; 14:86. PMID: 25890345; PMCID: PMC4411772.
      11. Cripe J, Eskander R, Tewari K. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. World J Clin Oncol. 2015 Apr 10; 6(2):16-21. PMID: 25866706; PMCID: PMC4390890.
      12. Eskander R, Lynch HT, Brown SM, Wagman LD, Tewari KS. Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome. Gynecol Oncol Rep. 2015 Apr; 12:31-3. PMID: 26076155; PMCID: PMC4442652.
      13. Longoria TC, Eskander R. Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov. 2015; 10(2):133-44. PMID: 25938471.
        View in: PubMed
      14. Eskander R, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol. 2015; 11(6):909-22. PMID: 25760973.
        View in: PubMed
      15. Eskander R, Tewari KS. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015 Jan 01; 37(1):20-38. PMID: 25592089.
        View in: PubMed
      16. Eskander R, Chang J, Ziogas A, Anton-Culver H, Bristow RE. Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population. J Clin Oncol. 2014 Dec 20; 32(36):4113-9. PMID: 25385738; PMCID: PMC4517941.
      17. Eskander R, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014 Nov; 6(6):280-92. PMID: 25364393; PMCID: PMC4206649.
      18. Eskander R, Tewari KS. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol. 2014 Nov; 7(6):847-58. PMID: 25301678.
        View in: PubMed
      19. Cripe J, Tseng J, Eskander R, Fader AN, Tanner E, Bristow R. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. Ann Surg Oncol. 2015 Feb; 22(2):655-61. PMID: 25155402.
        View in: PubMed
      20. Ji T, Eskander R, Wang Y, Sun K, Hoang BH, Guo W. Can surgical management of bone metastases improve quality of life among women with gynecologic cancer? World J Surg Oncol. 2014 Aug 05; 12:250. PMID: 25091036; PMCID: PMC4125343.
      21. Eskander R, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014 Aug; 26(4):314-21. PMID: 24979076.
        View in: PubMed
      22. Eskander R, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014 Jul; 25(3):249-59. PMID: 25045438; PMCID: PMC4102744.
      23. Eskander R, Tewari KS. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol. 2014 Sep; 7(5):613-22. PMID: 24984781.
        View in: PubMed
      24. Long B, Eskander R, Tewari KS. Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review. World J Radiol. 2014 Jun 28; 6(6):366-73. PMID: 24976937; PMCID: PMC4072821.
      25. Eskander R, Osann K, Dickson E, Holman LL, Rauh-Hain JA, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS. Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study. Gynecol Oncol. 2014 Aug; 134(2):379-84. PMID: 24887355; PMCID: PMC4191825.
      26. Hodeib M, Eskander R, Bristow RE. New paradigms in the surgical and adjuvant treatment of ovarian cancer. Minerva Ginecol. 2014 Apr; 66(2):179-92. PMID: 24848076.
        View in: PubMed
      27. Eskander R, Cripe J, Bristow RE. Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise. Curr Treat Options Oncol. 2014 Mar; 15(1):27-40. PMID: 24338278.
        View in: PubMed
      28. Eskander R, Tewari KS. American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer. Int J Gynecol Cancer. 2014 Jan; 24(1):13-8. PMID: 24300468; PMCID: PMC3907666.
      29. Eskander R, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014 Feb; 132(2):496-505. PMID: 24316305.
        View in: PubMed
      30. Eskander R, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol. 2013 Oct 03; 5(Suppl 1):55-61. PMID: 24124397; PMCID: PMC3795053.
      31. Eskander R, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer. 2013 Jul; 23(6):997-1005. PMID: 23792601; PMCID: PMC3694282.
      32. Ji T, Lin C, Krill LS, Eskander R, Guo Y, Zi X, Hoang BH. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer. 2013 Jun 10; 12:55. PMID: 23764122; PMCID: PMC3681603.
      33. Eskander R, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. Outside slide review in gynecologic oncology: impact on patient care and treatment. Int J Gynecol Pathol. 2013 May; 32(3):293-8. PMID: 23518913.
        View in: PubMed
      34. Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, Rooney K, Ji T, Eskander R, Zi X, Hoang BH. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma. 2013; 2013:147541. PMID: 23476112; PMCID: PMC3582188.
      35. Eskander R, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012; 4:395-404. PMID: 22927770; PMCID: PMC3422105.
      36. Eskander R, Randall LM, Sakai T, Guo Y, Hoang B, Zi X. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res. 2012 Aug; 38(8):1086-94. PMID: 22540374; PMCID: PMC3405181.
      37. Dellinger TH, Planutis K, Jandial DD, Eskander R, Martinez ME, Zi X, Monk BJ, Holcombe RF. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecol Oncol. 2012 Aug; 126(2):259-67. PMID: 22555103; PMCID: PMC3688285.
      38. Sakai T, Eskander R, Guo Y, Kim KJ, Mefford J, Hopkins J, Bhatia NN, Zi X, Hoang BH. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res. 2012 Jul; 30(7):1045-50. PMID: 22213202; PMCID: PMC3685290.
      39. Eskander R, Tarsa M, Herbst KD, Kelly TF. Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. J Obstet Gynaecol Res. 2011 Nov; 37(11):1731-3. PMID: 21790885.
        View in: PubMed
      40. Eskander R, Bristow RE, Saenz NC, Saenz CC. A retrospective review of the effect of surgeon specialty on the management of 190 benign and malignant pediatric and adolescent adnexal masses. J Pediatr Adolesc Gynecol. 2011 Oct; 24(5):282-5. PMID: 21600810.
        View in: PubMed
      41. Eskander R, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug; 205(2):103-10. PMID: 21411052.
        View in: PubMed
      42. Eskander R, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics. 2011; 5:1-5. PMID: 21383911; PMCID: PMC3044789.
      43. Eskander R, Scanderbeg D, Saenz CC, Brown M, Yashar C. Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy target and normal tissue contouring. Int J Gynecol Cancer. 2010 Jan; 20(1):47-53. PMID: 20130502.
        View in: PubMed
      44. Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, Moore TR, Resnik R. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol. 2010 Jan; 115(1):65-9. PMID: 20027036.
        View in: PubMed
      45. Warshak CR, Eskander R, Hull AD, Scioscia AL, Mattrey RF, Benirschke K, Resnik R. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):573-81. PMID: 16946217.
        View in: PubMed